Extended Data Fig. 2: Change from baseline in bodyweight at week 40 in the full analysis set. | Nature Medicine

Extended Data Fig. 2: Change from baseline in bodyweight at week 40 in the full analysis set.

From: Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

Extended Data Fig. 2

Changes from baseline in bodyweight were estimated using an ANCOVA with return-to-baseline multiple imputation for missing values at week 40 in patients who received at least 1 dose of study drug (5 mg, N = 230; 10 mg, N = 228; 15 mg, N = 229; insulin glargine, N = 220); statistical tests for 10 mg and 15 mg were two sided at a significance level of 0.025, statistical tests for 5 mg were two sided at a significance level of 0.05. Data presented are LSMean (SE). Error bars indicate SE. ANCOVA, analysis of covariance; LSMean, least-square mean; N, number of patients who were randomized and received at least 1 dose of study drug; SE, standard error.

Back to article page